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Recent evidence supports the hypothesis that cancer stem cells are responsible for tumour initiation and formation. Using flow
cytometry, we isolated a population of CD44
þCD24
  prostate cells that display stem cell characteristics as well as gene expression
patterns that predict overall survival in prostate cancer patients. CD44
þCD24
  cells form colonies in soft agar and form tumours in
NOD/SCID mice when as few as 100 cells are injected. Furthermore, CD44
þCD24
  cells express genes known to be important
in stem cell maintenance, such as BMI-1 and Oct-3/4. Moreover, we can maintain CD44
þCD24
  prostate stem-like cells as
nonadherent spheres in serum-replacement media without substantially shifting gene expression. Addition of serum results in
adherence to plastic and shifts gene expression patterns to resemble the differentiated parental cells. Thus, we propose that
CD44
þCD24
  prostate cells are stem-like cells responsible for tumour initiation and we provide a genomic definition of these cells
and the differentiated cells they give rise to. Furthermore, gene expression patterns of CD44
þCD24
  cells have a genomic signature
that is predictive of poor patient prognosis. Therefore, CD44
þCD24
  LNCaP prostate cells offer an attractive model system to
both explore the biology important to the maintenance and differentiation of prostate cancer stem cells as well as to develop the
therapeutics, as the gene expression pattern in these cells is consistent with poor survival in prostate cancer patients.
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Prostate cancer is the third leading cause of cancer-related deaths
among men, behind colon and lung cancer and leads all nonskin
cancer malignancies. This disease kills an estimated 27000
American men yearly with an estimated 230000 new cases
diagnosed (American Cancer Society, 2006). Treatment of prostate
cancer involves radiotherapy, surgery, hormone therapy, and
chemotherapy depending on the stage of the disease (Ngugi, 2007;
Ngugi and Magoha, 2007). Individuals who succumb to advanced
stages of prostate cancer inevitably become refractory to conven-
tional therapy, resulting in disease progression and death. A
growing body of evidence suggests cancer stem cells are the
putative mediators of chemotherapy resistance and tumour
progression (Dean et al, 2005). These resistant cells may be the
founder population that causes patient relapse and subsequent
metastasis. The cancer stem cell hypothesis suggests the existence
of a small subpopulation of cells within the tumour that give rise to
differentiated tumour cells. It is thought that the cancer stem cells
survive conventional treatment to later re-emerge more resistant to
therapy (Reya et al, 2001). To date, putative cancer stem cells have
been identified in blood (Bonnet and Dick, 1997), brain (Singh
et al, 2004), breast (Al-Hajj et al, 2003), lung (Kim et al, 2005), skin
(Fang et al, 2005), pancreas (Li et al, 2007), colon (O’Brien et al,
2007; Ricci-Vitiani et al, 2007), and prostate (Collins et al, 2005;
Patrawala et al, 2006).
Previous studies also demonstrated that putative breast and
brain cancer stem cells displayed a nonadherent phenotype, or
‘mammosphere’ and ‘neurosphere’ quality (Singh et al, 2004;
Ponti et al, 2005, respectively). Mammospheres were enriched with
CD44 and low for CD24 surface markers. When cultured in a
serum-replacement medium, the spheres maintained their stem
markers for months. However, with the addition of serum, the
CD44
þCD24
  cells differentiated into cells with an epithelial-like
morphology expressing mature markers of myoepithelial and
luminal cells (Ponti et al, 2005). Neurospheres are also enriched for
the extracellular marker, CD133. When putative neuronal stem
cells growing in serum-replacement media were exposed to serum
in vitro, the putative neuronal stem cells differentiated into
common medulloblastoma cell types and lost their CD133
expression (Singh et al, 2004).
Previously, CD44
þ prostate cancer cells were shown to have the
stem-like properties of increased tumorigenic, clonogenic, and
metastatic potential (Patrawala et al, 2006). CD44
þ from
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simmortalised prostate cancer cell lines formed colonies in soft agar
and tumours in NOD/SCID mice (Patrawala et al, 2006). However,
it was concluded in this study that the CD44
þ prostate cells were a
heterogenous population containing both primitive stem cells as
well as later progenitor cells. It has also been shown that
CD44
þCD133
þ integrin a2b1
high cells represent the tumorigenic
cells from prostate cancer patients (Collins et al, 2005). In breast
cancer, previous analysis identified CD44
þCD24
  cells as both
clonogenic and tumorigenic (Al-Hajj et al, 2003). Recently, work
with mouse prostate stem-like cells revealed commonalities
between mouse prostate stem-like cells and stem-like cells
originating from other tissues, including breast (Lawson et al,
2007).
Given this recent evidence, we sought to determine if human
prostate CD44
þCD24
  cells defined a population of cancer stem
cells. We also sought to determine the global molecular signatures
and the differentiation potential of these prostate cancer stem cells,
as these were issues not previously studied (Collins et al, 2005;
Patrawala et al, 2006). Here, we identify a rare subpopulation of
CD44
þCD24
  prostate cancer cells with stem-like characteristics
such as increased clonogenic and tumorigenic properties, and the
ability to grow as nonadherent spheres in serum-replacement
medium. These ‘prostatospheres’ display stem-like gene signatures
with high expression of ‘stemness’ genes including Oct-3/4, BMI-1,
smoothened, and b-catenin. Interestingly, addition of serum
resulted in the differentiation of the prostatospheres into an
adherent monolayer that genotypically resembles the bulk culture
of cells. Moreover, tumours from mice injected with CD44
þCD24
 
cells phenotypically resembled tumours removed from mice
injected with total LNCaP cells, indicating that CD44
þCD24
 
cells can give rise to the heterogeneous population present in
tumours derived from the LNCaP cell line. Additionally, the
CD44
þCD24
  cells contain a molecular signature originally
identified in breast tumorigenic cells (Liu et al, 2007) that can
predict patient outcome not only in breast cancer but also in
prostate cancer.
Overall, this study delineates an additional marker for prostate
cancer stemness an important step in developing effective
therapeutics against these important tumour initiators. Further-
more, we provide a genetic signature of the stem-like cells compared
with the differentiated cells to understand the underlying genetic
differences of these cells. In addition, the LNCaP CD44
þCD24
  cells
are an attractive model system to understand the biology of cancer
stem cells and their transition into later progenitor cells.
Importantly, the LNCaP CD44
þCD24
  cells provide an in vitro
model to develop therapeutics because they exhibit a genetic
signature reflective of patients that have a poor prognosis.
MATERIALS AND METHODS
Cells and media
LNCaP and DU145 cells were obtained from ATCC. LNCaP cells
were maintained in RPMI-1640þ10% fetal bovine serum
(FBS)þ2m ML -glutamineþpenicillin and streptomycin, and
DU145 cells were maintained in DMEMþ10% FBSþ2m M
L-glutamineþpenicillin and streptomycin. Following cell sorting,
cells were maintained in serum-replacement medium consisting
of DMEM:F12 plus 10ngml
 1 bFGF, 20ngml
 1 EGF, 5mgml
 1
insulin, and 0.4% BSA. For experiments describing the effects of
serum on CD44
þCD24
  cells, 10% FBS was added to the serum-
replacement medium for the indicated time.
Flow cytometric analysis and separation
LNCaP and DU145 cells were detached with trypsin, washed once
in FACs buffer (PBS containing 1–2% BSA and 5mM EDTA), then
stained with anti-CD24-FITC (Invitrogen, Carlsbad, CA, USA) and
anti-CD44-PE (Invitrogen) using 10ml of antibody per 10
6 cells,
and incubated at 41C for 15min. Following incubation, cells were
washed once with FACs buffer. For flow cytometric sorting,
cells were resuspended in FACs buffer at 20 10
6 cellsml
 1 and
separated on either an Aria cell sorter (BD Biosciences, San Jose,
CA, USA) or a MoFlo High Performance cell sorter (Dako
Cytomation, Carpinteria, CA, USA). Live cells were gated on the
basis of forward and side scatter, and single cells were gated on the
basis of forward scatter and pulse width (Supplementary Figure
1A). Gates were determined by analysis of unstained cells, isotype-
specific stains (Supplementary Figure 1B), and single stains (BD
Biosciences). The CD44
þCD24
  cells were not assessed for purity
due to the low numbers of cells obtained.
Real-time polymerase chain reaction
The expression of CD133 was measured on CD44
þCD24
  and
CD44
þCD24
 -depleted cells using Cells-to-CT kit (Applied
Biosystems, Foster City, CA, USA) and a StepOne Real-time
PCR machine (Applied Biosystems). A relative CT experiment was
performed using the TaqMan Gene Expression Assay reagent
(Applied Biosystems) for CD133 (PROM1, Hs00195682_m1) and
was normalised using GAPDH (Hs99999905_m1) and the supplied
enzyme mix in the Cells-to-CT kit.
Soft agar colony assay
Flow sorted cells were washed once in FACs buffer and 3000 cells
were suspended in either serum-replacement medium or
DMEMþ10% FBS containing 0.4% agarose and overlayed onto a
60-mm dish containing a solidified bottom layer of 0.4% agarose in
either serum-replacement or DMEMþ10% FBS. Once the top layer
solidified, 1ml of medium was placed on top to keep the plates moist.
Plates were incubated for 3 weeks until colonies were visible. The
p l a t e sw e r es t a i n e dw i t h1:7 5d i l u t i o no f0 . 3 3 %n e u t r a lr e ds o l u t i o n
(Sigma, Saint Louis, MO, USA) at 371C for 1h, then counted using an
Olympus CK2 microscope (Olympus, Center Valley, PA, USA) and
Image Pro Software (MediaCybernetics, Silver Spring, MD, USA).
Mouse xenograft studies
NCI-Frederick is accredited by AAALAC International and follows
the Public Health Service Policy for the Care and Use of Laboratory
Animals. Animal Care was provided in accordance with the
procedures outlined in the ‘Guide for Care and Use of Laboratory
Animals’ (Institute of Laboratory Animal Resources, 1996).
Following separation by flow cytometry, cells were placed in
serum-replacement medium overnight at a concentration of 1000
cellsml
 1. Cells were trypsinised, washed once with PBS, then
resuspended in serum-replacement medium at 1000 cells per 50ml,
mixed with an equal volume of matrigel (BD Biosciences) and
injected subcutaneous into male NOD/SCID mice (Jackson Labs,
Bar Harbor, ME, USA). Mice were monitored daily for palpable
tumour formation for a total of 159 days. Tumour size was
measured with calipers. Tumour volume was determined by the
following formula: V¼W
2 L/2 (Carlsson et al, 1983). Once
tumours reached greater than 1.5mm in one dimension, mice were
euthanised and tumours were extracted. For flow cytometric
analysis, tumours were dissociated with collagenase IV (Sigma)
using 200 unitsml
 1 in DMEM:F12 and incubated at 371C for 1.5h
with mechanical disruption every 30min. Cells were passed
through a 70-mm cell strainer and washed twice with FACs buffer.
RNA isolation, amplification, and microarray analysis
Total RNA was isolated with Trizol (Invitrogen). Following
isolation, RNA was amplified using Ambion’s MessageAmp II kit
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s(Ambion, Austin, TX, USA). Twenty-microgram-amplified RNA
was labelled in a reverse transcription (RT) reaction with an oligo-
dT primer, and either Cy3-dUTP or Cy5-dUTP. Following the RT
reaction, the RNA was hydrolysed by incubation with NaOH.
Probes were purified with a Microcon YM-30 column (Millipore,
Billerica, MA, USA). Oligonucleotide microarrays printed by the
NIH Microarray Core Facility were prehybridised in 5  SSC, 0.1%
SDS, and 1% BSA for 1h at 421C, washed in distilled water then
100% ethanol, and air dried. Hybridisation of mixed Cy-3- and
Cy-5-labelled probes was done in 50% formamide, 10  SSC, 0.2%
SDS overnight at 421C. After hybridisation, slides were washed in
decreasing concentrations of SSC (2  SSCþ0.1% SDS, 1  SSC,
and 0.2  SSC). Arrays were scanned in a GenePix 4000B scanner
and analysed using GenePix Pro (Molecular Devices, Sunnyvale,
CA, USA). Data analysis was performed using the centred
hierarchical clustering algorithm in Cluster and visualised using
TreeView, offered by Michael B Eisen as freeware (http://
rana.lbl.gov/EisenSoftware.htm).
RESULTS
Identification of a small CD44
þCD24
  subpopulation in
prostate cell lines with increased clonogenic properties
Given the reported similarity between murine breast and prostate
stem cells (Lawson et al, 2007) and the recent identification of a
CD44
þCD24
  subpopulation of breast cancer cells that have an
increased tumorigenic capacity (Al-Hajj et al, 2003), we sought to
identify and characterise CD44
þCD24
  cells in human prostate
cell lines. We identified a CD44
þCD24
  subpopulation with
varying abundance in different prostate cancer cell lines. In the
LNCaP cell line, the CD44
þCD24
  subpopulation was rare (0.04%)
(Figure 1A), whereas the DU145 cell line had a more prevalent
CD44
þCD24
  population (7–10%) (Figure 1B). As Collins et al
(2005) also showed that CD133 is a marker for prostate cancer
stem cells, we investigated the CD133 on CD44
þCD24
  and
CD44
þCD24
 -depleted LNCaP cells. LNCaP CD44
þCD24
  cells
have higher expression of CD133 as measured by real-time
polymerase chain reaction (Supplementary Figure 1C).
As anchorage-independent growth is an approximation of
tumorigenesis and cancer stem cells are thought to be the
tumour-initiating cells, we tested the ability of LNCaP
CD44
þCD24
  cells and CD44
þCD24
 -depleted cells to form
colonies in soft agar. There were a similar number of colonies
formed by the total LNCaP cells and the CD44
þCD24
 -depleted
cells (data not shown). Interestingly, the CD44
þCD24
  cells
formed approximately three times as many colonies as the
CD44
þCD24
 -depleted cells (Figure 1C). Thus, nearly all of the
3000 CD44
þCD24
  cells plated were able to initiate a colony
(colony-forming efficiency¼94%), with an average of 2830
colonies per plate. These results indicate that the CD44
þCD24
 
cells represent a near homogeneous population with respect to
colony-initiating ability. In addition, the colonies formed faster
(visually evident approximately 1 week earlier) and were generally
larger in size (approximately 1.5 times) than colonies from
CD44
þCD24
 -depleted cells (colonies stained at 12 days of
culturing are shown in Supplementary Figure 1D). The ability of
CD44
þCD24
 -depleted cells to form some colonies is likely a
result of the incomplete removal of all CD44
þCD24
  cells or may
indicate that a portion of these cells still maintain some stem-like
properties, although at a lesser extent than the CD44
þCD24
  cells.
Using cells purified from the DU145 cell line, we observed a two-
fold increase in the ability of CD44
þCD24
  cells in comparison
with CD44
þCD24
þ (Figure 1D). The fact that CD44
lo/  cells also
formed colonies at a rate similar to CD44
þ cells may result from
the low level of CD44 expression in the CD44
lo/  population, and
this population may in fact represent a transient amplifying cell.
Low numbers of CD44
þCD24
  cells, but not
CD44
þCD24
 -depleted cells, form tumours in NOD/SCID
mice
As the CD44
þCD24
  LNCaP cells formed colonies in soft agar
with high efficiency, we compared the ability of the CD44
þCD24
 ,
CD44
þCD24
 -depleted cells, and total LNCaP cells to initiate
tumours in NOD/SCID mice (Table 1). Either 100 or 1000 cells of
each of the populations were mixed with matrigel (1:1) and
injected subcutaneously into male NOD/SCID mice. As a positive
control for tumour formation, both 3 and 5 million total LNCaP
cells were also injected. Significantly, injection of 1000
CD44
þCD24
  cells resulted in tumours in 100% (5/5) of mice,
whereas 1000 CD44
þCD24
 -depleted cells failed to form tumours
in any mice (0/5). Injection of 1000 total LNCaP cells initiated a
tumour in only one out of five mice. Furthermore, injection of as
few as 100 CD44
þCD24
  cells resulted in a single tumour (1/5),
whereas 100 CD44
þCD24
 -depleted cells or 100 total LNCaP cells
were unable to form a tumour (0/5). Tumour formation with
DU145 showed an increase in the ability of CD44
þCD24
  cells to
form tumours (5/5) in comparison with CD44
þCD24
þ cells (3/5).
Moreover, while one mouse injected with CD44
þCD24
þ cells
formed a tumour in a similar time frame as mice injected with
CD44
þCD24
  cells, the other two mice that formed tumours had
an approximately 1 month longer latency period (Table 1).
Also interesting to note is the relative rate of tumour formation
of total LNCaP and total DU145. The DU145 cell line, in
comparison with the LNCaP cell line, contains a higher percentage
of CD44
þCD24
  cells (Figures 1A and B, respectively). In
concordance with the higher number of CD44
þCD24
  cells in
the DU145 cell line, NOD/SCID mice injected with 3 million
DU145 cells formed tumours earlier (approximately 9 days,
Table 1) that were 14 times larger at 39 days than NOD/SCID
mice injected with LNCaP cells (266.5 vs 18.2mm
3, respectively).
Taken together, this evidence supports the hypothesis that
CD44
þCD24
  cells are the tumour-initiating cells in the prostate
cancer cell lines. Given that the results obtained with the
subpopulations isolated from the LNCaP cell line showed a greater
difference in their abilities to both form colonies in soft agar and
tumours in NOD/SCID mice, we chose the LNCaP subpopulations
for further analyses.
Tumours removed from mice injected with CD44
þCD24
 
cells are differentiated and phenotypically resemble
tumours from mice injected with total LNCaP cells
Tumours excised from mice injected with either 1000
CD44
þCD24
  cells or 5 million total LNCaP cells were dissociated,
and expression patterns of CD44 and CD24 were analysed by flow
cytometry. Figure 2 shows a typical result for each tumour type.
Tumours from mice injected with CD44
þCD24
  cells recapitulate
the spectrum of cells obtained from tumours from mice injected
with total LNCaP cells, including CD44
þCD24
 , CD44
 CD24
þ,
and CD44
 CD24
  cells. The total LNCaP tumour showed
approximately twice as many CD44
þCD24
  cells compared with
the tumour derived from the CD44
þCD24
 -purified cells
(0.31 and 0.18%, respectively). This may be due to the fact that 5
million total LNCaP cells would be expected to contain approxi-
mately 2000 CD44
þCD24
  cells, whereas the tumours removed
from the CD44
þCD24
  cells were derived from the injection of
only 1000 CD44
þCD24
  cells. The ability of the CD44
þCD24
 
cells to give rise to the other cell types contained within the
tumours indicates that these are progenitor cells that still harbour
the ability to differentiate. Therefore, we have identified a
population of LNCaP cells that are stem-like in their biological
properties.
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sGene expression analysis of CD44
þCD24
  cells reveals
expression of genes that are important for stem cell
maintenance
Microarray analysis was performed on CD44
þCD24
 ,
CD44
þCD24
 -depleted, and total LNCaP cells. Analysis of genes
previously reported to be important for stem cell maintenance
show higher expression in CD44
þCD24
  cells relative to the other
cell populations (Figure 3A). The transcription factors Oct-3/4 and
BMI-1 are important for embryonic stem cell self-renewal (Niwa,
2001) and long-term proliferative capacity of normal haemato-
poetic and leukaemic stem cells (Valk-Lingbeek et al, 2004), and
are expressed in cancer stem-like cells (Tai et al, 2005; Patrawala
et al, 2006). An unsupervised analysis, where hierarchical
clustering was performed using all genes that were present on
80% of arrays and had a maximum–minimum value of greater
than 2 (5713 genes), revealed that CD44
þCD24
  cells have a gene
signature that differs significantly from both CD44
þCD24
 -
depleted and total LNCaP cells (Figure 3B). The large separation
of the dendogram likely reflects the significant differences in the
biology of the cell types. To determine which genes contribute to
the uniqueness of the CD44
þCD24
  cell signature, genes whose
expression differs by at least two-fold between the CD44
þCD24
 
cells and both the CD44
þCD24
 -depleted cells and the total
LNCaP cell line were identified. There were 88 genes that were
upregulated (Supplementary Table 1) and 255 genes that were
downregulated in the CD44
þCD24
  cells (Supplementary Table 2).
To determine the relationship of these genes, their functions were
analysed using Ingenuity System’s Pathways Analysis software.
Of the 343 genes showing at least a two-fold change in expression,
156 genes were found and analysed in the Ingenuity database. The
top 20 functional categories are shown in Figure 3C, and the
complete list of the genes in each category is in Supplementary
Table 3. Interestingly, the top categories such as cell-cycle
regulation, cell morphology, and cell-to-cell signalling are func-
tions known to differ between stem cells and differentiated cells. It
is also interesting to note that one of the categories is embryonic
development, suggesting similarities between the biology of
CD44
þCD24
  cells and cellular processes important in embryo-
genesis, including embryonic stem cells.
CD44
þCD24
  cells form spheres in serum-replacement
medium and shift phenotype in the presence of serum
Tumour stem cells should have the property of growing as large
unattached sphere in the absence of serum (Dontu et al, 2003; Lee
et al, 2006). LNCaP CD44
þCD24
  cells formed ‘prostatospheres’
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Figure 1 Identification and isolation of clonogenic CD44
þCD24
  cells in prostate cell lines. (A) LNCaP cells were analysed by flow cytometry for CD44
and CD24 expression. A small percentage of cells (0.04%) were found to be CD44
þCD24
 .( B) DU145 cells were analysed by flow cytometry for CD44
and CD24 expression. The gates shown were used for sorting of cells with the indicated phenotypes. The CD44
lo/  cells were the lowest 5% of the cells
with regards to CD44 staining. (C) The soft agar colony-forming efficiencies of both CD44
þCD24
  cells and CD44
þCD24
 -depleted LNCaP cells were
tested. The experiment was performed in triplicate and repeated, with a representative experiment shown. (D) The ability of the CD44
lo/ , CD44
þ,
CD44
þCD24
þ, and CD44
þCD24
  DU145 subpopulations was assessed for their ability to form colonies in soft agar. A representative experiment of two
performed in triplicate is shown.
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swhen placed in serum-replacement medium, whereas
CD44
þCD24
 -depleted cells grew as an attached monolayer in
the same medium (Figure 4A). The prostatospheres proliferate
slowly and could be maintained in culture for several weeks
without significant alteration of gene expression patterns as
compared with the freshly isolated CD44
þCD24
  cells (data not
shown). Addition of serum to CD44
þCD24
  prostatospheres
induces the cells to grow in an adherent monolayer similar to the
CD44
þCD24
 -depleted and total LNCaP cells (Figure 4B). Similar
adherent morphologies were observed with medium containing 1%
(data not shown) or 10% serum. This serum-dependent change in
growth pattern was also reported for glioblastoma stem cells (Lee
et al, 2006). Furthermore, the serum supplemented CD44
þCD24
 
cells recapitulated the differentiated phenotype of the total LNCaP
cells, with only a small percentage of CD44
þCD24
  cells present,
with the majority of the cells being CD44
 CD24
  (Figure 4C).
Thus, these data are consistent with the in vivo observations of
the CD44
þCD24
  cells differentiating into the heterogeneous cells
present in the parental LNCaP cell line and demonstrate that
CD44
þCD24
  LNCaP stem cells can give rise to differentiated cells
that display different surface markers.
CD44
þCD24
  cells grown in serum genotypically resemble
the parental LNCaP cell line
The addition of serum imparts significant morphological and
growth properties to the CD44
þCD24
  LNCaP cells. To determine
shifts in gene expression underlying the phenotypic changes
induced by serum addition, microarrays were performed on
CD44
þCD24
 , CD44
þCD24
 -depleted, and total LNCaP cells
grown for 7 days in serum-replacement media with and without
10% FBS added. Figure 3A reveals a serum-induced decrease in
expression of stem cell maintenance genes in the CD44
þCD24
 
cells; however, the CD44
þCD24
 -depleted cells and the total
LNCaP cells remained unchanged (Figure 5A). The decreased
expression of both Oct-3/4 and BMI-1 and the large shift in both
phenotype and genotype is consistent with these genes being key
regulators in the maintenance of stem cells (Niwa, 2001; Valk-
Lingbeek et al, 2004). Moreover, unsupervised cluster analysis of
4245 genes show a shift in the overall gene expression of the
CD44
þCD24
  cells grown in serum to resemble those of the total
LNCaP cell line (Figure 5B). Both of these results are consistent
with our previous observations that CD44
þCD24
  cells grown in
the presence of serum give rise to the heterogeneous cell types
present in the LNCaP cell line. In addition, we determined that 440
genes have at least a two-fold expression change upon addition of
serum to the CD44
þCD24
  cells but showed a smaller or no
change in both the CD44
þCD24
 -depleted and the total LNCaP
cells upon addition of serum (Supplementary Table 4). Analysis of
cellular functions using Pathway Analysis software, where 189
genes were available in their database, revealed that a large
Table 1 Tumour formation of prostate cancer subpopulations in NOD/
SCID mice
NOD/SCID mouse tumour formation with LNCaP subpopulations
LNCaP
subpopulation
No. of mice with
palpable tumours
Average time to tumour
formation (days)
1000
CD44
+CD24
 
5/5 81 (±12)
100 CD44
+CD24
  1/5 159
1000
CD44
+CD24
 -
depleted
0/5 —
100 CD44
+CD24
 -
depleted
0/5 —
1000 total LNCaP 1/5 89
100 total LNCaP 0/5 —
5 10
6 total
LNCaP
3/3 30.66 (±4)
*3 10
6 total
LNCaP
4/4 27.5 (±4)
NOD/SCID mouse tumour formation with DU145 subpopulations
DU145
subpopulation
No. of mice with
palpable tumours
Average time to tumour
formation (days)
100 CD44
+ 5/5 80 (±13)
100 CD44
  2/5 86 (±18)
100 CD44
+CD24
  5/5 80 (±3)
100 CD44
+CD24
+ 3/5 82 (+39)
*3 10
6 total
DU145
4/4 18 (±5)
Male NOD/SCID mice were injected subcutaneously with the indicated cell
phenotype and monitored for tumour formation. The table lists the subpopulations
tested, the total number of mice with palpable tumours, and the average number of
days until palpable tumour formation. A control of 5 million LNCaP cells was used.
To compare the relative tumour-forming abilities of LNCaP and DU145, 3 million
cells of each cell line was tested in an experiment independent of the experiment in
which the tumour-forming ability of the various subpopulations was tested
(designated by the asterisk).
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104
104
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101 102 103 104
CD24-FITC
C
D
4
4
-
A
P
C
101
102
103
104
C
D
4
4
-
A
P
C
Total LNCaP tumour CD44+CD24– tumour
Figure 2 Tumours isolated from mice injected with CD44
þCD24
  cells are phenotypically similar to tumours isolated from mice injected with total
LNCaP cells. Tumours were removed from mice injected with either 1000 CD44
þCD24
  cells or 5 10
6 total LNCaP cells. Once dissociated, the cells
were stained with anti-CD24-FITC and anti-CD44-PE, and the relative populations of cells were analysed by flow cytometry. The results shown are typical
results obtained from the analysis of three tumours from each injection group.
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sproportion was involved in cellular growth and proliferation
(Figure 5C). This is consistent with the increased growth rate that
was evident upon serum addition, but is not strictly a serum
response as several of these genes change in CD44
þCD24
  cells
upon the addition of serum but not in CD44
þCD24
 -depleted
cells or total LNCaP cells upon the addition of serum. Other
cellular function categories showing a high degree of change
include cancer, cell morphology, cell death, cellular assembly and
organisation, and molecular transport. A complete list of the
functions and the genes in each functional category is provided in
Supplementary Table 5.
The invasiveness gene signature is present in the
CD44
þCD24
  subpopulation isolated from LNCaP cells
Recently, Liu et al (2007) showed that a gene signature termed the
invasiveness gene signature (IGS) can predict overall patient
survival in breast, medulloblastoma, lung cancer, and prostate
cancer. The authors believe that, because the signature originated
from breast cancer cells displaying stem-like characteristics, the
IGS is predictive of tumours rich in stem cells, and subsequently
indicative of a poor prognosis. Since our CD44
þCD24
  cells were
isolated from a prostate cancer cell line, we searched for the
CD44+CD24–-depleted
Total LNCaP
CD44+CD24–
C
D
4
4
+
C
D
2
4
–
-
d
e
p
l
e
t
e
d
 
T
o
t
a
l
 
L
N
C
a
P
C
D
4
4
+
C
D
2
4
–
SMO
BMI-1
-Catenin
Oct-3/4
C
AB
02 –2 ≥4 ≤–4
Fold relative expression
Cancer
(27)
Cell cycle
(21)
Cell death
(19)
Haematological
development
and Function
(17)
Reproductive
system disease
(14)
Haematological 
disease (14)
Neurological 
disease (14)
Embryonic 
development (11)
Cell 
morphology  (10) Cell-to-cell signalling  
and interaction (10)
Cardiovascular system  
dev. and function (9) 
Skeletal and
muscular disorders (9) 
Cellular growth and proliferation (9) 
Gene
expression (8) 
Cellular
development (7) 
Tumor morphology (7) 
Connective tissue disorders (5)
Cardiovascular disease (5)
Immunological disease (5) Skeletal and muscular dev. and function (4)
Figure 3 CD44
þCD24
  cells express genes common to other stem-like cells and are genotypically distinct from both total LNCaP and CD44
þCD24
 -
depleted cells. (A) CD44
þCD24
  cells, CD44
þCD24
 -depleted cells, and total LNCaP cells were analysed using microarrays for genes expressed by
other stem-like cells. CD44
þCD24
  cells show higher expression of the genes analysed. (B) The relationship of CD44
þCD24
  cells, CD44
þCD24
 -
depleted cells, and total LNCaP cells based on gene expression of 5713 genes is shown. While total LNCaP and CD44
þCD24
 -depleted cells remain
together on a single branch, CD44
þCD24
  cells form a distinct branch, indicating a high degree of difference in their expression patterns for these genes.
(C) The top 20 functional categories of the genes showing an equal or greater than two-fold change in CD44
þCD24
  cells as compared with both
CD44
þCD24
 -depleted cells and the total LNCaP cells. The number of genes in each category is indicated in parentheses.
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spresence of the IGS in our LNCaP tumour-initiating cells. Of the
187 genes contained in the IGS, 118 of them were represented on
the arrays we used to compare CD44
þCD24
  cells to the parental
LNCaP cell line. Remarkably, there was a high statistical similarity
(Pearson’s correlation coefficient¼0.59) between our LNCaP
CD44
þCD24
  cells compared with the parental cell line and the
IGS generated by Liu et al from the comparison of breast
CD44
þCD24
  cells to normal epithelial cells (Supplementary
Table 6). The functions of the genes that show at least an
approximate two-fold change in expression in the same direction
between the IGS and the CD44
þCD24
  cells vs total LNCaP cells
(68/118¼57%, Pearson’s correlation coefficient¼0.73) were
classified according to function using Pathways Analysis. Of the
68 genes with this correlated expression, 43 were available for
analysis of function and are shown in Table 2. These include a
large number of transcriptional regulators and kinases as well as
numerous genes of unknown function. Thus, there is considerable
similarity between breast and prostate tumour-initiating cells,
and LNCaP CD44
þCD24
  cells provide a model system that may
be useful in understanding the properties of these important
A
B
C
0
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F
B
S
1
0
%
 
F
B
S
C
D
4
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-
P
E
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102
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+
C
D
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e
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t
e
d
C
D
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4
+
C
D
2
4
–
∗sub-cultured
Figure 4 CD44
þCD24
  cells form prostatospheres in serum-replacement media but become adherent and differentiate with the addition of serum. (A)
CD44
þCD24
  cells and CD44
þCD24
 -depleted cells were grown in serum-replacement medium for the indicated time. CD44
þCD24
 -depleted cells
grew as an adherent monolayer in this medium, reached confluency after 6 days and required subculturing as indicated on the picture at 20 days. However,
CD44
þCD24
  cells grew as nonadherent spheres, ‘prostatospheres’ that were not subcultured. Representative fields are shown at  10 magnification. (B)
Twenty-four hours after the addition of 10% serum, CD44
þCD24
  cells grew as an adherent monolayer. There are three representative fields shown at
 20 magnification. (C) Purified CD44
þCD24
  cells, grown in the presence of serum, shift expression of CD44 and CD24 to look like the original LNCaP
culture. CD44
þCD24
  cells were grown in medium containing 10% serum for 7 days and were then analysed for CD44 and CD24 expression by flow
cytometry.
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stumour-initiating cells, whose underlying biology predicts poor
clinical prognosis.
DISCUSSION
The CD44
þCD24
  prostate cancer cells are highly clonogenic and
tumorigenic cells. Moreover, they grow in an anchorage-indepen-
dent manner and proliferate slowly in serum-replacement
medium. Importantly, when these cells are depleted from the
LNCaP cell line, the remaining cells are unable to initiate tumour
formation in NOD/SCID mice. Furthermore, the tumours that arise
in mice injected with purified CD44
þCD24
  LNCaP cells are
phenotypically diverse, containing primarily CD44
 CD24
  and
CD44
 CD24
þ cells and only a small percentage of CD44
þCD24
 
cells, similar to tumours derived from injecting the total LNCaP
cell line. Likewise, when CD44
þCD24
  cells are grown in serum-
containing medium, they phenotypically and genotypically
recapitulate the heterogeneity found within the parental cell line.
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o
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Cellular growth 
and proliferation
(49)
Cancer
(40)
Cell morphology (28)
Cell death 
(27)
Cellular assembly
and organisation
(24)
Molecular transport 
(22) Genetic disorder
(17)
Cell cycle
(16)
Cell-to-cell signalling
and interaction (14)
Cellular movement  (11)
Protein trafficking
(11)
Reproductive system
dev. and function(11)
Organ dev. (8)
Skeletal and muscular disorder (7)
Endocrine system disorder (6)
Respiratory disease (6)
Energy production(2)
Connective tissue disorder (4) 
Posttranslation modification (5) Developmental disorder (6)
CD44+CD24–-depleted
Total LNCaP
CD44
+CD24–
Figure 5 CD44
þCD24
  cells grown in serum-containing medium genomically resemble the parental LNCaP cell line. CD44
þCD24
 , CD44
þCD24
 -
depleted, and total LNCaP cells were grown in either serum-replacement medium alone or serum-replacement medium plus 10% FBS for 1 week.
(A) Expression of genes important in stem cell biology showed higher expression in freshly isolated CD44
þCD24
  cells. The graph shows the log2-fold
changes in expression between cells grown in the presence of serum vs the same cells grown in the absence of serum. The value provided for b-catenin is an
average of two array elements. (B) Unsupervised hierarchical cluster analysis of arrays was performed. Array tree is based on expression patterns of 4245
genes. (C) The top 20 functional categories of genes showing an equal to or greater than two-fold change in CD44
þCD24
  cells grown in serum vs without
serum as compared with both CD44
þCD24
 -depleted cells and the total LNCaP cells. The number of genes in each functional category is indicated in
parentheses.
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þCD24
  cells are the clonogenic,
tumorigenic cells contained within the LNCaP cell line and that
they give rise to the multiple cell types, thereby satisfying the
conventional criteria of a cancer stem cell.
Patrawala et al (2006) recently showed that CD44
þ cells derived
from prostate cell lines are enriched in tumour progenitor
cells, and Collins et al (2005) have demonstrated that
CD44
þa2b1
hiCD133
þ cells from patients are highly tumorigenic.
Patrawala et al (2006) stated that approximately 80% of their
CD44
þ cells were CD44
þa2b1
hiCD133
þ, and they concluded that
prostate carcinoma is likely comprised of multiple populations of
cells that are able to give rise to tumours with differing efficiencies.
Consistent with these findings, the CD44
þCD24
  cells isolated
from LNCaP cells also express CD133
þ (Supplementary Figure 1C).
Interestingly, integrin a2 expression is increased when the
CD44
þCD24
  cells were cultured in serum-containing medium
(Supplementary Table 4). The induction of surface integrin
a2b1 remains to be determined due to the low number of cells
that are obtained with sorting CD44
þCD24
  cells. While both of
the previously identified populations (CD44
þ and
CD44
þa2b1
hiCD133
þ) can give rise to tumours and likely also
represent progenitor cells, the increase in the expression of
integrin a2 in the CD44
þCD24
  cells grown in serum, coupled
with the ability of these cells to recapitulate the heterogeneity seen
within the LNCaP cell line, suggests that the CD44
þCD24
  cells,
which also express CD133, could be a more primitive cell than
either the CD44
þ cells or the CD44
þa2b1
hiCD133
þ progenitor
cells. In agreement with this data, Tang et al (2007) have recently
discussed a hierarchical organisation of prostate stem cells, which
places CD44
þ cells as an earlier stem cell than the CD44
þa2b1
hi
cells. Our data suggest that the absence of the CD24 marker
together with expression of the CD44 marker (i.e., CD44
þCD24
 )
may identify a very early cancer progenitor cell, or the cancer stem
cell itself, but further studies with side-by-side comparisons of
these populations are needed to properly assign this hierarchy.
Generally, stem cells are thought to be largely quiescent and to
proliferate slowly, eventually giving rise to progenitors that have
faster proliferation rates (Tang et al,2 0 0 7 ) .T h u s ,t h es l o w
proliferation of CD44
þCD24
  cells in culture further supports the
idea that this subpopulation of cells most likely represents an early
progenitor/stem cell. In addition, one of the largest differences in gene
functions between CD44
þCD24
  cells compared with either CD44
þ
CD24
 -depleted or total LNCaP cells was ‘cell cycle’ (Figure 5C),
again highlighting the fact that these are largely quiescent cells.
There are several important therapeutic implications in the
identification of cancer stem cells. Prostate cancer stem cells are
largely undifferentiated and quiescent cells. Meanwhile, conven-
tional chemotherapy generally targets the highly proliferative,
more differentiated cells leaving behind the cancer stem cells.
This can be highlighted by the fact that breast cancer patients
whose tumours have gene expression patterns resembling breast
cancer stem cells have a poorer prognosis (Liu et al, 2007).
Consequently, the identification of the cancer stem cell and an
understanding of the mechanisms driving its self-renewal and
differentiation pathways are paramount to targeting and to
hopefully eradicating the tumour. To develop effective chemother-
apeutic agents, we first need to identify the earliest cancer stem cell
and understand its biology; tasks that can be difficult with the
limited patient material that is often available from prostatec-
tomies. The recent identification of the IGS as a prognostic
indicator in prostate cancer and the correlation with its presence in
a subset of the LNCaP cell line, suggest that CD44
þCD24
  LNCaP
cells can serve as a model system. Thus, the identification of an
in vitro model system relevant to patient survival provides an
invaluable tool, not only to further our understanding of how these
cells self-renew and form tumours, but also to develop effective
therapeutics.
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